What Femodette Treats: Main Uses and Benefits

Femodette is indicated primarily for highly reliable, reversible contraception as a proactive method of family planning. Beyond birth control, the medication is commonly used to help manage specific symptomatic patterns. It is applied across domains where additional symptomatic support is needed, addressing conditions characterized by fluctuating manifestations. These include symptomatic relief for severe menstrual pain (dysmenorrhea), excessive bleeding (menorrhagia), and moderate acne.

---

Core Therapeutic Benefits

Femodette is commonly used as a systematic method for women seeking to manage their fertility. The key therapeutic benefit contributes to periods that are often lighter, less painful, and generally more regular, which assists with maintaining functional stability and reducing the daily strain caused by distressing menstrual manifestations. For skin concerns, it may be part of symptomatic management by addressing acne, contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Support for Symptoms related to Painful Periods
Symptom: Severe menstrual cramps and pain (Dysmenorrhea)
Therapeutic Benefit: Assists with maintaining comfort during symptomatic periods.
Context: Relevant in situations where symptoms interfere with daily functioning.

Regulatory References

1. Oral Contraceptive Pills - NIH National Library of Medicine

Who Can and Cannot Use Femodette

Femodette is indicated only for women of reproductive age who do not present any specific health conditions or risk factors defined as absolute exclusions by regulatory authorities. The official eligibility profile is dominated by contraindications related to thromboembolic risk and hormone-sensitive conditions.

---

Eligibility Status	Non-Eligible Populations (As Officially Labeled)
Contraindicated	Women with current or history of Venous or Arterial Thromboembolism (VTE/ATE) or a known predisposition for blood clots.
Contraindicated	Women with a history of breast cancer, liver tumours, or severe hepatic disease until liver function has fully normalized.
Contraindicated	Women with current or history of migraine with focal neurological symptoms or established cerebrovascular disease.
Contraindicated	Individuals with known or suspected pregnancy or those receiving specific HCV antiviral therapy.
Restricted Use	Individuals requiring major surgery or experiencing prolonged immobilisation; the medicine must be stopped four weeks prior.
Not Recommended	Women who are currently breastfeeding (lactating) in the immediate post-partum period.

---

The medicine is not indicated for use in the pre-menarche or post-menopausal populations. Increasing age, particularly above 35 years, is officially noted as a risk factor for thromboembolism.

Interaction Map: Interactions with other medicines and products — official regulatory information for Femodette

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Hepatic enzyme inducers, Strong CYP3A4 inhibitors, Hepatitis C combination regimens, Thyroid Hormone Replacement Therapy, other hormonal contraceptives.
Specific interacting medicines (if explicitly listed)	Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Glecaprevir/Pibrentasvir, Rifampicin, Carbamazepine, Phenytoin, Ketoconazole, Tizanidine, Lamotrigine, St. John's Wort.
Mechanistic basis of interactions (only if stated in label)	Hepatic Cytochrome P450 Enzyme Induction (reducing contraceptive exposure); CYP Inhibition (increasing co-administered drug exposure); Glucuronidation Induction (reducing Lamotrigine exposure); Increased plasma concentration of Thyroid-Binding Globulin (TBG).
Timing-based interaction rules (if applicable)	Non-hormonal contraception must be continued for 28 days following the discontinuation of a hepatic enzyme-inducing medicine due to enzyme de-induction time.
Population-specific interaction notes (if applicable)	Severe hepatic disease or liver tumours lead to poor metabolism of steroid hormones, which is the basis for a restriction of use in this population.
Interaction-related restrictions	Co-administration with specific Hepatitis C combination regimens is formally prohibited due to the documented risk of liver enzyme elevation. Concurrent use of other hormonal contraceptives is restricted.

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation
Interaction severity classification (as defined in official documents)	Contraindicated Combinations (e.g., specific Hepatitis C regimens); Clinically Significant Interactions (resulting in reduced efficacy or increased exposure/risk).
Regulatory basis (EMA / FDA / etc.)	Interaction data is documented in official government labeling across multiple jurisdictions.
Interaction-context constraints (as defined in official documents)	Efficacy may be reduced if vomiting or severe diarrhoea occurs within 4 hours of administration, as this impairs absorption.

Resulting Interaction Structure

Official interaction statements:

• Co-administration with certain Hepatitis C combination regimens is formally contraindicated due to the officially documented risk of liver enzyme elevation.
• Medicines classified as hepatic enzyme inducers (e.g., Rifampicin, Phenytoin) are documented to reduce the plasma concentrations of Ethinyl Estradiol and Gestodene, which compromises contraceptive effectiveness.
• The contraceptive significantly increases the plasma concentration of co-administered drugs like Tizanidine by inhibiting its CYP1A2 metabolism.
• The regulatory label mandates the use of non-hormonal contraception for a duration of 28 days after stopping a hepatic enzyme-inducing medicine.

Connection to the overall interaction profile (2–4 sentences): The overall regulatory interaction profile is defined by pharmacokinetic interactions involving enzyme induction or inhibition, which leads to the critical risk of reduced contraceptive efficacy or increased drug exposure. This structure necessitates specific regulatory constraints, including formally contraindicated combinations and mandatory post-treatment timing rules for enzyme inducers, as stated in government prescribing information. The profile also addresses pharmacodynamic effects such as the alteration of binding proteins and restrictions based on underlying patient conditions that impact steroid hormone metabolism.

Femodette contains gestodene, a synthetic progestogen, and ethinylestradiol, a synthetic estrogen, which exert their primary effects via the hypothalamic-pituitary-ovarian (HPO) axis and reproductive tract tissues.

Gestodene acts as an agonist at the intracellular progesterone receptor (PR). This agonism primarily modifies gene transcription to suppress the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This downstream signal attenuation reduces the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland, thereby inhibiting folliculogenesis and the mid-cycle LH surge. The system-level consequence is the prevention of ovulation.

Both components also modulate peripheral tissues. Ethinylestradiol acts as an agonist at the intracellular estrogen receptor (ER). Combined hormonal signaling alters the endometrium, rendering it unreceptive to blastocyst implantation, and induces physicochemical changes in the cervical mucus, increasing its viscosity to impede sperm transit through the cervix into the upper genital tract.

Official Administration Guidelines

Route of Administration and Dosing Schedule

Femodette tablets are for oral use only. The dosage regimen is one tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval.

Each tablet should be swallowed whole, with liquid if necessary. To maintain contraceptive protection, the tablet must be taken at approximately the same time each day. Starting the next pack must occur after the 7-day interval, even if bleeding (withdrawal bleed) is still present. Starting the tablet-taking on the first day of the menstrual cycle (Day 1 of bleeding) is recommended to ensure immediate contraceptive efficacy.

---

Missed Dose Instructions

If a dose is missed, the course of action depends on the duration of delay:

• Delay less than 12 hours: Take the missed tablet immediately and continue taking the rest of the pack at the usual time. Contraceptive protection is maintained.
• Delay more than 12 hours: Contraceptive protection may be reduced. The user should take the last missed tablet immediately (even if it means taking two tablets in one day) and follow specific instructions based on the week of the cycle:
  • Week 1 (Days 1–7): Use a barrier method (e.g., condoms) for the next 7 days. If sexual intercourse occurred in the 7 days before the missed dose, the possibility of pregnancy should be considered.
  • Week 3 (Days 15–21): To prevent reduced efficacy, the user must omit the 7-day tablet-free interval and start the new pack immediately after finishing the current one. If the tablets were taken correctly in the 7 days prior to the missed dose, no additional barrier methods are necessary.

Femodette: Overview of Clinical Data

Femodette is a combined oral contraceptive pill containing the synthetic hormones ethinylestradiol (an estrogen) and gestodene (a third-generation progestin). The clinical efficacy of this combination is primarily established through its dual hormonal action. Studies show that the main contraceptive effect is achieved by inhibiting the release of an egg from the ovaries (ovulation). Secondary mechanisms, supported by clinical observation, include thickening the cervical mucus—which impedes sperm movement—and altering the uterine lining, which makes implantation more difficult.

Efficacy and Safety Profile

Clinical trials determine the efficacy of combined oral contraceptives like Femodette using the Pearl Index, which measures the number of unintended pregnancies per 100 woman-years of use. When taken consistently and correctly, this type of pill demonstrates a high level of effectiveness for pregnancy prevention.

In terms of safety, the use of any combined hormonal contraceptive (CHC) is associated with an increased risk of venous thromboembolism (VTE), or blood clots in the veins, compared to non-users. Clinical research has suggested that products containing the third-generation progestin gestodene, such as Femodette, may carry a slightly higher VTE risk compared to some second-generation progestins, such as levonorgestrel. However, the absolute number of VTE events remains rare.

Observed non-contraceptive effects documented in clinical settings, similar to other CHCs, include a reduction in painful and heavy menstrual bleeding. Common side effects reported during trials included headaches, nausea, and breast tenderness. These effects are generally observed to decrease over the initial months of use.

Key Studies & References

1. Combined hormonal contraceptives and the risk of venous thromboembolism: A systematic review and meta-analysis
2. NICE Guideline NG10: Contraception
3. Mechanism of Action of Combined Oral Contraceptives: Ovulation Suppression, Cervical Mucus Thickening, and Endometrial Effects

Common questions about Femodette (FAQ)

---

Q: How does Femodette differ from other combined contraceptive pills?

Femodette is a combined oral contraceptive that contains a low dose of ethinylestradiol (an estrogen) and gestodene, which is classified as a third-generation progestin. Official product information notes that combined hormonal contraceptives are associated with a VTE risk, and products with gestodene are classified as having a potentially higher risk compared to some with levonorgestrel.

Q: What are the most common side effects of Femodette?

The adverse reactions most commonly reported in regulatory safety data include headache, nausea, abdominal pain, breast pain or tenderness, weight increase, and mood changes (which may include depressed mood).

Q: How long does it typically take for the body to adjust to Femodette?

Clinical observations referenced in the official documents suggest that common side effects, such as headaches and nausea, are generally seen to decrease over the initial months of use as the body adjusts to the hormonal components.

Q: Can taking antibiotics reduce the effectiveness of Femodette?

Certain medicines classified as hepatic enzyme inducers, which include some antibiotics such as rifampicin, are documented in official sources to reduce the levels of the contraceptive hormones in the blood. This reduction is documented to compromise the medicine's effectiveness. Other broad-spectrum antibiotics are generally not classified as having this type of interaction.

Q: Do herbal supplements, like St. John's wort, interact with Femodette?

Yes, St. John's Wort is explicitly listed in regulatory documents as an interacting substance. It has the potential to act as a hepatic enzyme inducer, which can reduce the effectiveness of the contraceptive. This interaction is documented in official government prescribing labels.

Q: Can medication for epilepsy or seizures interfere with Femodette?

Official interaction maps show that certain medicines used for epilepsy or seizures, such as carbamazepine and phenytoin, are classified as hepatic enzyme inducers. These substances are documented to decrease the levels of the contraceptive hormones in the body, which compromises the medicine's effectiveness.

Q: Does Femodette affect blood pressure?

Regulatory documents state that very high blood pressure is a risk factor that can restrict the use of combined contraceptives. A significant rise in blood pressure is also listed in official documents as a risk factor or a contraindication for continued use.

Q: What official research has been done on the effects of Femodette?

The efficacy of the medicine for pregnancy prevention is established through clinical trials and is measured using the Pearl Index, which tracks the rate of unintended pregnancies. Official research also covers the safety profile, including the documented risk of venous thromboembolism (VTE) associated with the specific hormone combination.

Q: What is the purpose of the pill-free interval?

The administration schedule is designed with 21 active tablets followed by a 7-day tablet-free interval. This specific regimen is structured to allow for a withdrawal bleed, which mimics the natural timing of a woman's menstrual cycle.

Q: Do many people experience weight gain while taking Femodette?

Weight increase is documented in the safety profile as a Very Common to Common adverse reaction. This means it is one of the more frequently reported effects in regulatory data.

Q: Does Femodette cause changes in mood or anxiety levels?

The safety profile lists mood changes, including depressed mood, as a Very Common to Common adverse reaction.

Q: Does alcohol intake affect how Femodette works?

The official constraints indicate that if vomiting or severe diarrhoea occurs within four hours of administration, absorption is impaired, which may lead to reduced efficacy. This is the main documented way consumption could indirectly impact effectiveness.

Q: What is the difference between the two hormones in Femodette?

Femodette contains ethinylestradiol (an estrogen) and gestodene (a progestogen). The two components achieve their effect by targeting different receptors to suppress ovulation and alter the uterine lining, which prevents pregnancy.

Q: How does the level of estrogen in Femodette compare to other pills?

Femodette is classified as a fixed, low-dose blend, featuring a low concentration of the estrogen component, ethinylestradiol. This low-dose formulation is characteristic of many modern combined oral contraceptives, as noted in official sources.

Q: Can certain medical tests be affected by taking Femodette?

Official information documents that the contraceptive can cause changes in the body, such as increasing the plasma concentration of Thyroid-Binding Globulin (TBG), which may affect the results of related medical tests.

Q: Are there any long-term health concerns associated with using Femodette for many years?

Regulatory documents indicate that the use of combined hormonal contraceptives is associated with a rare, serious risk of venous thromboembolism (VTE), which is noted to be highest during the first year of use. The official eligibility criteria also note that increasing age, particularly above 35 years, is a related risk factor for thromboembolism.

Q: Is there a link described between Femodette and potential mood swings?

The safety profile lists 'mood changes' as a Very Common to Common adverse reaction, according to official product information.

How to Store and Dispose of Femodette

Official Storage Requirements

Femodette tablets must be stored under specific regulatory conditions to maintain stability. The product must be kept at a temperature below 25 C and remain protected from light. This protection is ensured by keeping the tablets in their original blister pack. When stored correctly, the medicine maintains an approved shelf life of 3 years.

All medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Femodette must not be discarded in household waste or flushed into wastewater systems. The officially mandated procedure is to return the unwanted product to a local pharmacy. The pharmacy will ensure safe handling and disposal of the medicine as pharmaceutical waste, preventing environmental contamination.